ATE528397T1 - Bei krebs überexprimiertes gen - Google Patents

Bei krebs überexprimiertes gen

Info

Publication number
ATE528397T1
ATE528397T1 AT04771625T AT04771625T ATE528397T1 AT E528397 T1 ATE528397 T1 AT E528397T1 AT 04771625 T AT04771625 T AT 04771625T AT 04771625 T AT04771625 T AT 04771625T AT E528397 T1 ATE528397 T1 AT E528397T1
Authority
AT
Austria
Prior art keywords
gene
cancer
nucleotide sequence
protein
seq
Prior art date
Application number
AT04771625T
Other languages
English (en)
Inventor
Hiroyuki Aburatani
Yoshitaka Hippo
Hirokazu Taniguchi
Yong Xin Chen
Shumpei Ishikawa
Shin-Ichi Fukumoto
Takahiro Shimamura
Naoko Kamimura
Ying Qiu Guo
Shogo Yamamoto
Yukio Ito
Hirotaka Ito
Toshihiko Ohtomo
Original Assignee
Perseus Proteomics Inc
Chugai Pharmaceutical Co Ltd
Hiroyuki Aburatani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perseus Proteomics Inc, Chugai Pharmaceutical Co Ltd, Hiroyuki Aburatani filed Critical Perseus Proteomics Inc
Application granted granted Critical
Publication of ATE528397T1 publication Critical patent/ATE528397T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
AT04771625T 2003-08-08 2004-08-06 Bei krebs überexprimiertes gen ATE528397T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003290704 2003-08-08
PCT/JP2004/011650 WO2005014818A1 (ja) 2003-08-08 2004-08-06 癌高発現遺伝子

Publications (1)

Publication Number Publication Date
ATE528397T1 true ATE528397T1 (de) 2011-10-15

Family

ID=34131599

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04771625T ATE528397T1 (de) 2003-08-08 2004-08-06 Bei krebs überexprimiertes gen

Country Status (5)

Country Link
US (1) US20080153104A1 (de)
EP (2) EP2311468B1 (de)
JP (2) JP4643450B2 (de)
AT (1) ATE528397T1 (de)
WO (1) WO2005014818A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1733743A4 (de) * 2004-04-09 2007-06-27 Takeda Pharmaceutical Präventiv-/heilmittel gegen krebs
JP5007238B2 (ja) * 2005-01-06 2012-08-22 ジェネンテック， インコーポレイテッド 癌の予後予測、診断および治療に有用な方法および組成物
US7932032B2 (en) * 2005-05-02 2011-04-26 Toray Industries, Inc. Method for diagnosing esophageal cancer
WO2007005635A2 (en) * 2005-07-01 2007-01-11 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mitotic spindle protein aspm as a diagnostic marker for neoplasia and uses therefor
JP2008118915A (ja) * 2006-11-10 2008-05-29 Kazuto Nishio 胃癌高発現遺伝子特定による胃癌診断および創薬への利用
US20100111852A1 (en) * 2006-12-14 2010-05-06 Forerunner Pharma Research Co., Ltd. Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same
EP2060583A1 (de) * 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identifikation Tumor-assoziierter Marker für Diagnose und Therapie
EP2095821A1 (de) * 2008-02-29 2009-09-02 Rheinische Friedrich-Wilhelms-Universität Bonn Antikrebsmittel
JP2009276153A (ja) * 2008-05-13 2009-11-26 Sumitomo Bakelite Co Ltd 胃癌の判定方法
FR2958936A1 (fr) * 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
US9119869B2 (en) * 2010-04-29 2015-09-01 Ronald J. Shebuski Mucin derived polypeptides
WO2011152071A1 (ja) * 2010-06-04 2011-12-08 花王株式会社 新規ヒアルロン酸分解促進因子及びその阻害剤
SG10201506782XA (en) * 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
PT2643019T (pt) * 2010-11-24 2019-04-23 Lexicon Pharmaceuticals Inc Anticorpos para notum pectinacetilesterase
US20190382853A1 (en) * 2011-02-25 2019-12-19 Korea Institute Of Ocean And Science & Technology Mest as biomarker for cancer diagnosis and prognosis and method for using thereof
EP2773665A1 (de) * 2011-11-01 2014-09-10 Bionomics, Inc. Antikörper und verfahren zur behandlung von krebs
EP2773373B1 (de) 2011-11-01 2018-08-22 Bionomics, Inc. Verfahren zur blockierung eines krebsstammzellenwachstums
WO2013104102A1 (zh) * 2012-01-09 2013-07-18 苏州工业园区为真生物医药科技有限公司 乳腺癌诊断和预示的标志物
WO2013104103A1 (zh) * 2012-01-09 2013-07-18 苏州工业园区为真生物医药科技有限公司 诊断和预示肠癌的标志物
CN103940996B (zh) * 2013-05-07 2016-03-16 上海良润生物医药科技有限公司 Cystatin SN和AFP在制备诊断和预示肝癌标志物中的应用
CN103901206B (zh) * 2013-05-07 2016-03-16 上海良润生物医药科技有限公司 半胱氨酸蛋白酶抑制剂sn与糖类抗原19-9的联合应用
JP6614582B2 (ja) 2014-04-04 2019-12-04 バイオノミクス インコーポレイテッド Ｌｇｒ５に結合するヒト化抗体
WO2015172201A1 (en) * 2014-05-16 2015-11-19 Peter Maccallum Cancer Institute Biomarker of gastric cancer
US10745487B2 (en) 2016-03-22 2020-08-18 Bionomics Limited Method of treating cancer by administering an anti-LGR5 monoclonal antibody
WO2024076781A1 (en) * 2022-10-08 2024-04-11 Taipei Medical University Polynucleotides for silencing transcript variant 1 of assembly factor for spindle microtubules and applications thereof

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK0479909T3 (da) 1989-06-29 1997-04-07 Medarex Inc Bispecifikke reagenser til AIDS-behandling
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
CA2102511A1 (en) 1991-05-14 1992-11-15 Paul J. Higgins Heteroconjugate antibodies for treatment of hiv infection
DE69229477T2 (de) 1991-09-23 1999-12-09 Cambridge Antibody Tech Methoden zur Herstellung humanisierter Antikörper
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JPH08334280A (ja) 1995-04-07 1996-12-17 Fuji Koki Seisakusho:Kk 膨張弁及び冷凍システム
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6337195B1 (en) 1995-06-06 2002-01-08 Human Genome Sciences, Inc. Colon specific genes and proteins
EP0857780A4 (de) * 1995-09-14 2001-12-05 Sumitomo Electric Industries Neue proteine die ausgezeichnet in leberkrebs expremiert werden, gene die diese proteine kodieren, antikörper gagegen und geeignete methoden
JPH09203734A (ja) * 1996-01-26 1997-08-05 Sumitomo Electric Ind Ltd 抗血清、抗体、リガンド及びそれらの検出方法
GB9607441D0 (en) 1996-04-10 1996-06-12 Univ Manitoba Human hyaluronan receptor
CN100335501C (zh) 1996-09-26 2007-09-05 中外制药株式会社 抗人副甲状腺激素相关蛋白的抗体
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1630235A3 (de) 1997-02-25 2009-05-27 Corixa Corporation Zusammensetzungen für die Immundiagnose von Prostatakrebs und Methoden für deren Anwendung
WO2000006698A1 (en) 1998-07-30 2000-02-10 Human Genome Sciences, Inc. 98 human secreted proteins
WO1998042738A1 (en) * 1997-03-21 1998-10-01 Human Genome Sciences, Inc. 87 human secreted proteins
EP1016717A4 (de) * 1997-06-26 2004-11-17 Sumitomo Electric Industries Neues protein exprimiert in leberkrebs, gen kodierend dafür, antikörper dagegen und ein verfahren zum nachweis der expression dieses proteins
DE69816467T2 (de) 1997-10-20 2004-04-15 The Regents Of The University Of California, Oakland Robo: eine familie polypeptiden und nukleinesäuren wirksam in nervenzellleitung
EP1037925A2 (de) 1997-12-09 2000-09-27 Children's Medical Center Corporation Antagonisten für die neuropilin rezeptorfunktion und deren verwendung
US6362321B1 (en) 1998-03-27 2002-03-26 The General Hospital Corporation Taxol resistance associated gene
EP1108021A2 (de) 1998-08-31 2001-06-20 Bayer Corporation Humane gene differentiell exprimiert in kolorektalkrebs
WO2001064835A2 (en) 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2000034477A2 (en) 1998-12-11 2000-06-15 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
EP1144632A3 (de) 1998-12-23 2001-11-07 Corixa Corporation Verbindungen zur immunotherapie und diagnose von dickdarmkrebs und verfahren zu ihrer anwendung
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
CA2369319A1 (en) 1999-03-15 2000-09-21 Eos Biotechnology, Inc. Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
EP1165784A2 (de) 1999-03-31 2002-01-02 Curagen Corporation Nukleinsäuren mit offener leserahmen, die polypeptiden kodieren; "orfx"
EP3031917A1 (de) 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Verfahren zur steuerung der aktivität von immunologisch funktionellen molekülen
WO2000073509A2 (en) 1999-06-01 2000-12-07 Incyte Genomics, Inc. Molecules for diagnostics and therapeutics
AU769143B2 (en) 1999-06-30 2004-01-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
WO2001009318A1 (fr) 1999-07-29 2001-02-08 Helix Research Institute Genes associes au cancer du foie
WO2001021653A2 (en) 1999-09-23 2001-03-29 Corixa Corporation Ovarian tumor antigen and methods of use therefor
US20030003538A1 (en) * 1999-09-23 2003-01-02 Dietrich Paul Shartzer Neuropathic pain genes; compositions thereof; related reagents
AU7721500A (en) 1999-09-29 2001-04-30 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
WO2001051513A2 (en) 2000-01-14 2001-07-19 Corixa Corporation Ovarian tumor-associated sequences
AU2001229340A1 (en) 2000-01-14 2001-07-24 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20020090615A1 (en) * 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020042096A1 (en) 2000-01-31 2002-04-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
DE10004102A1 (de) 2000-01-31 2002-06-20 Metagen Pharmaceuticals Gmbh Nachweis von differenzieller Genexpression
WO2001055448A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001059111A1 (en) 2000-02-08 2001-08-16 Millennium Pharmaceuticals, Inc. 18057 protein, a seven transmembrane protein
AU2001241541A1 (en) 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU4347701A (en) 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
JP2001245671A (ja) 2000-03-07 2001-09-11 Chiba Prefecture ヒト神経芽細胞腫においてクローニングされた新規遺伝子及び新規遺伝子の断片
AU2001249317A1 (en) 2000-03-21 2001-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer
WO2001073027A2 (en) 2000-03-24 2001-10-04 Corixa Corporation Compositions and methods for therapy and diagnosis of colon cancer
AU2001253140A1 (en) 2000-04-03 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Tumor markers in ovarian cancer
US20020068288A1 (en) 2000-04-11 2002-06-06 Lodes Michael J. Compositions and methods for the therapy and diagnosis of lung cancer
AU6503901A (en) 2000-05-26 2001-12-11 Univ Illinois Reagents and methods for identifying and modulating expression of genes regulated by retinoids
WO2001094629A2 (en) 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
AU2001266787A1 (en) 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
WO2002000939A2 (en) 2000-06-28 2002-01-03 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating colon cancer
JP4791676B2 (ja) 2000-06-29 2011-10-12 生化学工業株式会社 硫酸基転移酵素及び該酵素をコードするｄｎａ
AU2002218770A1 (en) 2000-07-11 2002-01-21 Corixa Corporaton Compositions and methods for the therapy and diagnosis of lung cancer
US20040092724A1 (en) 2000-07-28 2004-05-13 Mcguckin Michael Andrew Mucin
WO2002010217A2 (en) 2000-08-02 2002-02-07 The Johns Hopkins University Endothelial cell expression patterns
WO2002012280A2 (en) 2000-08-03 2002-02-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
AU2001294719A1 (en) 2000-09-29 2002-04-08 Incyte Genomics, Inc. Secreted human proteins
AU2001294943A1 (en) 2000-10-02 2002-04-15 Bayer Corporation Nucleic acid sequences differentially expressed in cancer tissue
WO2002031140A1 (fr) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Cellules produisant des compositions d'anticorps
AU2002246519A1 (en) 2000-11-20 2002-08-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002046415A2 (en) * 2000-12-08 2002-06-13 Incyte Genomics, Inc. Polynucleotide and polypeptide sequences of putative transporters and ion channells
AU2002255478A1 (en) * 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US6743619B1 (en) * 2001-01-30 2004-06-01 Nuvelo Nucleic acids and polypeptides
AU2002251841A1 (en) 2001-01-30 2002-08-12 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
WO2002064797A2 (en) 2001-02-16 2002-08-22 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Mitochondrial topoisomerase i
EP1293569A3 (de) * 2001-09-14 2004-03-31 Research Association for Biotechnology Vollständige cDNA-Sequenzen
US20040038223A1 (en) * 2001-10-02 2004-02-26 Glennda Smithson Novel proteins and nucleic acids encoding same
WO2003061681A2 (en) * 2002-01-25 2003-07-31 DeveloGen Aktiengesellschaft für entwicklungsbiologische Forschung Proteins involved in the regulation of energy homeostasis and organelle metabolism
JP2006513702A (ja) * 2002-09-09 2006-04-27 ヌラ インコーポレーティッド Ｇタンパク質共役受容体およびその使用
EP1556490A4 (de) * 2002-10-22 2006-04-05 Nuvelo Inc Neue nukleinsäuren und polypeptide
US20070020637A1 (en) * 2003-01-21 2007-01-25 Research Association For Biotechnology Full-length cDNA
WO2004087874A2 (en) * 2003-03-28 2004-10-14 Nuvelo, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
EP2311468A1 (de) 2011-04-20
US20080153104A1 (en) 2008-06-26
EP1652923A1 (de) 2006-05-03
JP2011015681A (ja) 2011-01-27
JPWO2005014818A1 (ja) 2006-10-05
WO2005014818A1 (ja) 2005-02-17
JP4643450B2 (ja) 2011-03-02
EP1652923B1 (de) 2011-10-12
EP2311468B1 (de) 2014-01-15
EP1652923A4 (de) 2006-07-26

Similar Documents

Publication Publication Date Title
ATE528397T1 (de) Bei krebs überexprimiertes gen
AU7633001A (en) Diagnosis of diseases associated with apoptosis
BRPI0519766A2 (pt) proteases Ácidas féngicas
ATE446380T1 (de) Methode zur dns-sequenzierung
ATE471370T1 (de) Varianten von beta-glukosidasen
CY1107335T1 (el) ΝΕΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΚΑΙ ΠΟΛΥΠΕΠΤΙΔΙΑ ΤΟΥ ΓΟΝΙΔΙΟΥ IFNα-17
BRPI0403221A (pt) Fragmento de taq polimerase termoestável
RS92704A (en) Immunoglobulin-domain containing cell surface recognition molecules
DK1536006T3 (da) Cancerantigener og anvendelse deraf
ATE340856T1 (de) Mit schizophrenie zusammenhängendes gen und protein
WO2009044085A3 (fr) Oligonucleotides, utilisation, methode de detection et kit permettant de diganostiquer la presence du gene e1 du virus de chikungunya
WO2006016172A3 (en) Cell surface glycoprotein
WO2003020887A3 (en) Gene identification
DE602006004966D1 (de) Intrinsic-faktor vom schwein
WO2002083081A3 (en) Prostate cancer-related compositions, methods and kits based on dna macroarray protemics platforms
ATE348172T1 (de) Verfahren zur herstellung von coenzym q 10
DE50111824D1 (de) Diagnose von mit humos assoziierten krankheiten
ATE414905T1 (de) Diabetesmodell
WO2004096021A3 (en) Global analysis of transposable elements as molecular markers of cancer
WO2002101002A3 (en) Identification of snps the hgv-v gene
ATE311459T1 (de) Die ltr-region von msrv-1 und die durch sie kodierten proteine, und sonden und methoden für detektion des msrv-1 retrovirus
WO2001051518A3 (en) Nucleic acids encoding human semaphorin proteins and use thereof
NO20011961D0 (no) PRV-1-genet og anvendelsen av dette
ATE449180T1 (de) Transglutaminase genprodukte
DE602004017488D1 (de) Neuer vektor und nutzung davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties